Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | CTSK | P43235 | 10/20 | 0.43 |
| ▸ | CTSS | P25774 | 6/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | CA7 | P43166 | 1/20 | 0.41 |
| ▸ | CTSL | P07711 | 2/20 | 0.40 |
| ▸ | CTSB | P07858 | 1/20 | 0.40 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.40 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.40 |
| ▸ | RELA | Q04206 | 1/20 | 0.40 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | CA12 | O43570 | 1/20 | 0.39 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.39 |
| ▸ | PPARG | P37231 | 1/20 | 0.39 |
| ▸ | PPARA | Q07869 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL475731 | 1.00 | CYP1A2 (0.46) | CYP1A2CYP2C9CYP2C19HTTCTSK | |
| SCHEMBL14649972 | 1.00 | CYP1A2 (0.46) | CYP1A2CYP2C9CYP2C19HTTCTSK | |
| SCHEMBL30759429 | 0.92 | CYP1A2 (0.47) | CYP1A2CYP2C9CYP2C19HTTCTSK | |
| SCHEMBL29727304 | 0.92 | CYP1A2 (0.47) | CYP1A2CYP2C9CYP2C19HTTCTSK | |
| SCHEMBL5758063 | 0.91 | CTSK (0.48) | CYP1A2CYP2C9CYP2C19HTTCTSK | |
| SCHEMBL13405220 | 0.91 | CTSK (0.48) | CYP1A2CYP2C9CYP2C19HTTCTSK | |
| SCHEMBL5317755 | 0.88 | CTSK (0.46) | CYP1A2CYP2C9CYP2C19HTTCTSK | |
| SCHEMBL21853151 | 0.88 | CTSK (0.46) | CYP1A2CYP2C9CYP2C19HTTCTSK | |
| SCHEMBL21853149 | 0.88 | CTSK (0.46) | CYP1A2CYP2C9CYP2C19HTTCTSK | |
| SCHEMBL2074722 | 0.88 | CTSK (0.46) | CYP1A2CYP2C9CYP2C19HTTCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12377100-B2 | Toll like receptor modulator compounds | GILEAD SCIENCES, INC. (US) | 2025-08-05 | — | — | US | disclosed |
| US-20220305115-A1 | COMBINATION OF HEPATITIS B VIRUS (HBV) VACCINES AND PYRIDOPYRIMIDINE DERIVATIVES | Janssen Sciences Ireland Unlimited Company (IE) | 2022-09-29 | — | — | US | disclosed |
| US-20220218709-A1 | TOLL LIKE RECEPTOR MODULATOR COMPOUNDS | GILEAD SCIENCES, INC. | 2022-07-14 | — | — | US | disclosed |
| US-20220220519-A1 | Transaminase mutant and use thereof | ASYMCHEM LIFE SCIENCE (TIANJIN) CO., LTD. (CN) | 2022-07-14 | — | — | US | disclosed |
| EP-3964571-A1 | TRANSAMINASE MUTANT AND APPLICATION THEREOF | Asymchem Life Science (Tianjin) Co., Ltd. (CN) | 2022-03-09 | — | — | EP | disclosed |
| WO-2021077425-A1 | TRANSAMINASE MUTANT AND USE THEREOF | 凯莱英医药化学（阜新）技术有限公司 | 2021-04-29 | — | — | WO | disclosed |
| US-10919851-B2 | 2-pyrrolidine phenylhydrazides antibacterial agents | ABAC Therapeutics, S.L. (ES) | 2021-02-16 | — | — | US | disclosed |
| US-10919851-B2 | 2-pyrrolidine phenylhydrazides antibacterial agents | ABAC Therapeutics, S.L. (ES) | 2021-02-16 | — | — | US | disclosed |
| WO-2020255038-A1 | COMBINATION OF HEPATITIS B VIRUS (HBV) VACCINES AND PYRIDOPYRIMIDINE DERIVATIVES | Janssen Sciences Ireland Unlimited Company (IE) | 2020-12-24 | — | — | WO | disclosed |
| WO-2020237552-A1 | TRANSAMINASE MUTANT AND APPLICATION THEREOF | 凯莱英生命科学技术(天津)有限公司 | 2020-12-03 | — | — | WO | disclosed |
| US-20130059840-A1 | SULFONAMIDO PYRROLIDINE COMPOUNDS WHICH INHIBIT BETA-SECRETASE ACTIVITY AND METHODS OF USE THEREOF | COMENTIS, INC. (US) | 2013-03-07 | — | — | US | disclosed |
| US-20120295894-A1 | PYRROLIDINE COMPOUNDS WHICH INHIBIT BETA-SECRETASE ACTIVITY AND METHODS OF USE THEREOF | BILCER GEOFFREY M (US) | 2012-11-22 | — | — | US | disclosed |
| US-20120214802-A1 | PYRROLIDINE COMPOUNDS WHICH INHIBIT BETA-SECRETASE ACTIVITY AND METHODS OF USE THEREOF | PURDUE RESEARCH FOUNDATION | 2012-08-23 | — | — | US | disclosed |
| EP-2486006-A1 | SULFONAMIDO PYRROLIDINE COMPOUNDS WHICH INHIBIT BETA-SECRETASE ACTIVITY AND METHODS OF USE THEREOF | COMENTIS, INC. (US) | 2012-08-15 | — | — | EP | disclosed |
| EP-2411000-A1 | PYRROLIDINE COMPOUNDS WHICH INHIBIT BETA-SECRETASE ACTIVITY AND METHODS OF USE THEREOF | COMENTIS, INC. (US) | 2012-02-01 | — | — | EP | disclosed |
| US-20110286969-A1 | DEUTERATED COMPOUNDS AS HEPATITIS C VIRUS (HCV) INHIBITORS | SCHERING CORPORATION (US) | 2011-11-24 | — | — | US | disclosed |
| EP-2349244-A1 | PYRROLIDINE COMPOUNDS WHICH INHIBIT BETA-SECRETASE ACTIVITY AND METHODS OF USE THEREOF | COMENTIS, INC. (US) | 2011-08-03 | — | — | EP | disclosed |
| WO-2011044057-A1 | SULFONAMIDO PYRROLIDINE COMPOUNDS WHICH INHIBIT BETA-SECRETASE ACTIVITY AND METHODS OF USE THEREOF | COMENTIS, INC. (US) | 2011-04-14 | — | — | WO | disclosed |
| WO-2010110817-A1 | PYRROLIDINE COMPOUNDS WHICH INHIBIT BETA-SECRETASE ACTIVITY AND METHODS OF USE THEREOF | COMENTIS, INC. (US) | 2010-09-30 | — | — | WO | disclosed |
| WO-2010042892-A1 | PYRROLIDINE COMPOUNDS WHICH INHIBIT BETA-SECRETASE ACTIVITY AND METHODS OF USE THEREOF | COMENTIS, INC. (US) | 2010-04-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130059840-A1 | SULFONAMIDO PYRROLIDINE COMPOUNDS WHICH INHIBIT BETA-SECRETASE ACTIVITY AND METHODS OF USE THEREOF | BACE1, BACE2, GSAP | CYP1A2 4674/4885CYP2C9 4600/4885CYP2C19 4629/4885 |
| US-20220218709-A1 | TOLL LIKE RECEPTOR MODULATOR COMPOUNDS | TLR8, TLR3, TLR6 | CYP1A2 4675/4885CYP2C9 4746/4885CYP2C19 4677/4885 |
| US-20120295894-A1 | PYRROLIDINE COMPOUNDS WHICH INHIBIT BETA-SECRETASE ACTIVITY AND METHODS OF USE THEREOF | BACE1, BACE2, APP | CYP1A2 4473/4885CYP2C9 4696/4885CYP2C19 4673/4885 |
| US-12377100-B2 | Toll like receptor modulator compounds | TLR8, TLR3, TLR6 | CYP1A2 4675/4885CYP2C9 4746/4885CYP2C19 4677/4885 |
| US-10919851-B2 | 2-pyrrolidine phenylhydrazides antibacterial agents | ATAD2, ATAD2B, ATAD5 | CYP1A2 547/4885CYP2C9 1693/4885CYP2C19 1130/4885 |
| US-20120214802-A1 | PYRROLIDINE COMPOUNDS WHICH INHIBIT BETA-SECRETASE ACTIVITY AND METHODS OF USE THEREOF | BACE1, BACE2, APP | CYP1A2 4473/4885CYP2C9 4696/4885CYP2C19 4673/4885 |
| US-20110286969-A1 | DEUTERATED COMPOUNDS AS HEPATITIS C VIRUS (HCV) INHIBITORS | PEPD, PREP, ACE | CYP1A2 285/4885CYP2C9 286/4885CYP2C19 280/4885 |
| US-20220305115-A1 | COMBINATION OF HEPATITIS B VIRUS (HBV) VACCINES AND PYRIDOPYRIMIDINE DERIVATIVES | HAVCR2, ENTPD5, HMGB3 | CYP1A2 336/4885CYP2C9 813/4885CYP2C19 1051/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.